Exenatide
Exenatide was the first licensed GLP-1 receptor agonist, developed from exendin-4 found in Gila monster venom. Randomized comparative trials show...
About:
The first GLP-1 receptor agonist approved for type 2 diabetes, derived from exendin-4 in Gila monster venom.
What does this peptide do?
Supported by randomised human trials. Research focuses on type 2 diabetes.
Type 2 diabetes
The first GLP-1 agonist approved for type 2 diabetes.
Evidence grade
AHighest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.
What are the benefits and side effects of this peptide
What research says it may help with
- Randomized comparative trials show improved glycaemic control, and pooled analyses show weight reduction.
- It is a licensed medicine with decades of trial evidence behind it.
Who should avoid it
- People who are pregnant or breastfeeding
- Children outside licensed indications
- People with a history of pancreatitis, pending clinician advice
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
See the safety section. Absence of a flag is not evidence of safety.
A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.
How to store this peptide
Supplied as a prefilled pen or vial in the licensed product. Store refrigerated before first use and follow the product leaflet.
Lyophilized storage
Refrigerate at 2–8 °C in the original carton. Do not freeze.
Reconstituted storage
Once in use, may be kept below 30 °C for the period stated on the product label.
Storage Handling
Protect from light. Do not use if it has been frozen.
Related research
Related research is coming soon for this peptide.
Related peptides
MetabolicTirzepatide
Dual GIP/GLP-1 receptor agonist studied for weight management and glucose control.
MetabolicSemaglutide
GLP-1 receptor agonist researched for appetite regulation and metabolic health.
MetabolicRetatrutide
Triple-receptor agonist explored for next-generation weight management research.